Mya Caryn Schiess, M.D 2

CURRICULUM VITAE

NAME: Mya Caryn Schiess, M.D. January 2011

PRESENT TITLE: Professor of Neurology, Adriana Blood Endowed Chair in Neurology Vice-Chair, Department of Neurology Director, Movement Disorder Fellowship Program Director, Post Graduate Medical Education Program Clinical Director, Movement Disorders/Neurodegenerative Diseases UT MOVE

ADDRESS: The University of Texas-Houston Health and Science Center Department of Neurology 6431 Fannin, MSB 7.044 Houston, Texas 77030 (713) 500-7121

Laboratory: Cell Cultures , CSF analysis, Intracellular Electrophysiology/Neuropharmacology, HPLC 6431 Fannin, MSB 7.306 Houston, Texas 77030 (713) 500-7073

CITIZENSHIP: United States of America

UNDERGRADUATE EDUCATION:

1969-1973 Bachelor of Arts The University of California at Double Major Experimental Berkeley Psychology & Physiology Berkeley, California

RESEARCH TRAINING:

06/1975 – Post Baccalaureate Research: The University of New Mexico 09/1975 Factors governing female Departments of Psychology and menstrual cycles. Physiology Dennis Feeney, Ph.D.

09/1975- Graduate Studies: The University of New Mexico 01/1976 Research in stereotaxic Departments of Psychology and neurosurgery including mapping Physiology the rat brain for self-stimulation Dennis Feeney, Ph.D. Mya Caryn Schiess, M.D 2 Curriculum Vitae

with microelectrode implants

GRADUATE EDUCATION:

1976-1980 Medical Doctorate The University of New Mexico School of Medicine Albuquerque, New Mexico

MEDICAL SCHOOL RESEARCH ACTIVITIES:

06/1977- Medical Student Research The University of New Mexico School 09/1977 Program; NSF student Research of Medicine Grant: Development of Endocrine Laboratory Radioreceptor assay for Albuquerque, New Mexico somatostatin. Glen Peake, M.D.

06/1978- Pharmacological studies of The University of New Mexico School 09/1978 anterior pituitary hormone of Medicine release and concentrations of Endocrine Laboratory GH, TRH, SRIF, and PR Albuquerque, New Mexico following morphine and Glen Peake, M.D. naloxone in rats.

POST GRADUATE TRAINING:

1980-1981 Internship Parkland Memorial Hospital and Internal Medicine Veterans Administration Hospital, The University of Texas Health Science Center, Southwestern Medical School, Dallas, Texas Roger N. Rosenberg, M.D., Chairman

1981-1984 Residency Parkland Memorial Hospital and Neurology Veterans Administration Hospital, The University of Texas Health Science Center, Southwestern Medical School, Dallas, Texas Roger N. Rosenberg, M.D., Chairman

1984-1986 Fellowship The University of Texas Southwestern Neurophysiology Medical School, Dallas, Texas /Pharmacology Research Department of Physiology Robert Moss, Ph.D. 1986-1989 Fellowship The University of Texas Medical Neurophysiology Branch-Galveston, Texas Mya Caryn Schiess, M.D 3 Curriculum Vitae

/Pharmacology Research Department of Pharmacology Patricia Gallagher, Ph.D.

ACADEMIC APPOINTMENTS:

1984 – 1985 Instructor of Physiology and Department of Physiology Neurology The University of Texas Southwestern Medical School, Dallas, Texas

1986-1987 Instructor Research of Department of Pharmacology Pharmacology and Neurology The University of Texas Medical Branch-Galveston, Texas

1987-1989 Assistant Professor of Department of Neurology and Joint Appt Pharmacology and Clinical Department of Pharmacology Neurology The University of Texas Medical Branch at Galveston Galveston, Texas

1989-1996 Assistant Professor of Department of Neurology, Joint Appt Neurology and Department of Pharmacology and of Pharmacology and Toxicology Toxicology The University of Texas Medical Branch at Galveston Galveston, Texas

1996-1999 Assistant Professor of Department of Neurology Neurology The University of Texas Medical Branch at Galveston Galveston, Texas

1999-2001 Assistant Professor of Department of Neurology Neurology The University of Texas Houston Health Science Center Houston, Texas

2001-2006 Associate Professor of Department of Neurology Neurology The University of Texas Houston Director, Movement Disorder Health Science Center Fellowship Program Houston, Texas Director, Neurology Residency Program

Professor of Neurology 9/2006 Vice Chair, Dept. of Neurology Mya Caryn Schiess, M.D 4 Curriculum Vitae

OTHER DEPARTMENTAL AFFILIATIONS/RESPONSIBILITIES

12-2009 TEACHING FACULTY FOR SLEEP MEDICINE FELLOWSHIP- DIRECTOR RICHARD CASTRIOTTA, MD

JANUARY 2010 CORE TEACHING FACULTY FOR NEUROLOGY- DIRECTOR PHILIP ORLANDER, MD

HOSPITAL APPOINTMENTS:

1980-1987 Full-Active Privileges Dallas County Parkland Hospital Dallas, Texas

1980-1987 Full-Active Privileges Veteran’s Affairs Hospital Dallas, Texas

1987-1999 Full-Active Privileges John Sealy Hospital Galveston, Texas

1995-2005 Consultant Privileges MHMR Richmond State School Richmond, Texas

1999- Full-Active Privileges Memorial Hermann Hospital Present Houston, Texas

1999- Full-Active Privileges Texas Institute of Rehabilitation and Present Research Houston, Texas

2000- Full-Active Privileges LBJ General Hospital Present Houston, Texas

2002- Full-Active Privileges St. Luke’s Episcopal Hospital Present Houston, Texas

2005-2008 Full-Active Privileges Methodist Hospital Houston, Texas

LICENSURE:

Texas Medical License G7427 American Board of Psychiatry and 48016 Neurology Membership Issued: 1995 Mya Caryn Schiess, M.D 5 Curriculum Vitae

Renewal: 2014

CERTIFICATIONS:

Texas Department of Public Safety Certificate T0061774 Drug Enforcement Agency Certificate AS3107186 ACLS Certificate

HONORS AND AWARDS:

1971 Phi Beta Kappa from the University of California, Berkeley 1980 Alpha Omega Alpha from The University of New Mexico Medical School 1984 Physician Scientist Award (K-11) NICHHD 1999-2009 Award recipient for The University of Texas at Houston Medical School “Dean’s Excellence in Teaching Award” 2007 Houston Area Parkinson Society Annual Awards- Recipient of Roy H. Cullen Quality of Life Award with others on HAPS Medical Advisory Committee 2007- Adriana Blood Endowed Chair in Neurology in recognition and support for PRESENT Vice Chair responsibilities, leadership, research projects and educational goals and programs.

PROFESSIONAL ORGANIZATIONS AND COMMITTEES

LOCAL: 1992 - Present Texas Medical Association 1998 - Present Texas Neurological Society

NATIONAL: 1971 - Present Phi Beta Kappa Chapter Member 1976 - Present Alpha Omega National Society Member 1982 - Present American Medical Association 1986 - Present Society for Neuroscience 1987 - Present The New York Academy of Sciences 1993 - Present American Academy of Neurology 1998 - Present Movement Disorder Society 1999 - Present National Stroke Association 1999 – Present International Essential Tremor Foundation

CURRENT EDITORIAL POSITIONS: January 2008 Editorial Board for Archives of Neurology 2000-Present Reviewer for Archives of Neurology

2004-Present Reviewer for the American College of Physicians

2005-Present Reviewer for Trends in Pharmacological Sciences Mya Caryn Schiess, M.D 6 Curriculum Vitae

SERVICE ON NATIONAL GRANT REVIEW PANELS, STUDY SECTIONS, COMMITTEES:

1999-Present Reviewer for The University of Texas at Houston Department of Neurology “Young Investigator Award”

National Student Research Forum Grant Reviews for the National Science Foundation 2008 - present Neurology Residency Program Directors Focus Group- Develop curriculum for teaching DBS therapies to Neurology residents

CURRENT SERVICE ON THE UNIVERSITY OF TEXAS- HOUSTON HEALTH SCIENCE CENTER COMMITTEES:

2000 Committee on Committees

2002 Liaison Committee on Medical Education Clinical Departments/GME/CME

2002 Curriculum Committee

2000 - Present Health Science Center Research Council

2003 - Present Continuing Medical Education Committee for the Association of University Professors in Neurology

2004 - Present Curriculum Committee for M.D. Program

2004 - Present Search Committee for a Director of Neuroscience Institute of Molecular Medicine 2009 Search Committee for Chair of PM&R

2006, 2009 Committee on Committees

PAST SERVICE ON COMMITTEE FOR THE UNIVERSITY OF TEXAS- MEDICAL BRANCH AT GALVESTON

1993 – 1999 Pharmacy and Therapeutics Committee

1993 – 1998 Active/Voting member “Guidelines for the Management of Vascular Headaches” Mya Caryn Schiess, M.D 7 Curriculum Vitae

1993 - 1998 Active/Voting member: “Guidelines for the Management of Seizure Disorders”

1994 Appointed member of TDCJ Formulary Committee

1995 - 1999 Member of Neurology CME Accreditation Committee

CURRENT SERVICE ON GRADUATE SCHOOL COMMITTEES FOR THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON:

1999 - Present Neuroscience Research Center Member

2000 - Present Graduate Medical Education Committee Member

2003 - Present Graduate Medical Education Internal Review Executive Committee

2004 - Present The University of Texas Health Science Center at Houston Graduate Medical Education Committee

PAST SERVICE ON GRADUATE SCHOOL COMMITTEES FOR THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON:

1994 – 1995 Active member for the Integrated Learning Tract alternative curriculum committee for review and implementation of cases for the Case Based Learning Integrative Learning Tract

1995 - 1999 Member of Neurology Curriculum Committee for the Neurology Residency Three Year Academic Program (including weekly teaching sessions)

SERVICE TO THE COMMUNITY:

1987 - 1999 Volunteer Physician Work at St. Vincent’s House Free Medical Clinic, Galveston, Texas

1995 –2005 Neurology consultant: Richmond State School MHMR Facility Richmond, Texas

2003- 2006 Subspecialty Movement Disorders Clinic at LBJ County Hospital, Monthly- referred patients form all County Hospitals and Clinics 2006- present Houston Area Parkinson Society Member Medical Advisory Committee Mya Caryn Schiess, M.D 8 Curriculum Vitae

2006 Presentations at October and April half-day educational conferences- “Overview of PD”, “PD Treatment Overview”, “Non-motor Symptoms of PD” 2007 Presentations at October and April half-day educational conferences- “Overview of PD”, “PD Treatment Overview”, “Non-motor Symptoms of PD” 2008 HAPS –Annual Update April 23, 2008- Presented “Update on PD Research” 2009 Presentations at October and April half-day educational conferences- “Overview of PD”, “PD Treatment Overview”, “Non-motor Symptoms of PD”

SPONSORSHIP OF CANDIDATES FOR POSTGRADUATE DEGREE:

Eva Ma, M.D., PhD 1995 Clinical Advisor – The University of Texas Medical Branch at Galveston

Ashley Cain 2001-2003 Masters Thesis Committee for Masters Degree candidate in Neuroscience, University of Texas Health Science Center at Houston Ashley Jagar 2004 Academic Advisory Committee for Neuroscience Pre Doctoral Graduate Student, University of Texas Health Science Center at Houston

Ashley Jagar Hood 2005-2009 Supervisory Committee for PhD Thesis PhD received July 2009, Doctorate in Neuroscience

SPONSORSHIP OF POSTDOCTORAL FELLOWS:

Ali Alrefai, M.D. 2001-2002 Movement Disorder Fellow, University of Texas Houston Medical School Jerome Lisk, M.D. 2002-2003 Movement Disorder Fellow, University of Texas Houston Medical School Rob Izor, M.D. 2003-2004 Movement Disorder Fellow, University of Texas Houston Medical School Stanley Fisher, M.D. 2004-2005 Movement Disorder Fellow, University of Texas Houston Medical School Fernando Acosta, M.D. 2005-2006 Movement Disorder Fellow, University of Texas Houston Medical School Erin (Stimming) Furr, 2006-2007 Movement Disorder Fellow, University of Texas M.D. Houston Medical School Irene Oh, M.D. 2007-2009 Movement Disorder Fellow, University of Texas

Anita Madan, MD 2008-2010 Movement Disorder Fellow, University of Texas Mya Caryn Schiess, M.D 9 Curriculum Vitae

Toby Yaltho, MD 2008-2009 Movement Disorder Fellow, University of Texas

Benjanin Glenn Kidder, 2009-2010 Movement Disorder Fellow, University of Texas MD

Ashley Jagar 2005-2006 Co-Director/Sponsor for Doctoral Graduate Student, Ruth L.Kirschstein National Research Service Award Individual Fellowship, “Deep Brain Stimulation & Attention in Parkinson Disease” , Depts of Neurobiology and Neuroanatomy and Neurology, University of Texas Health Science Center at Houston

Ashley Jagar Hood 2007-2009 Doctoral Thesis Committee; earned PhD in Neurosciences July 2009.

CURRENT TEACHING RESPONSIBILITIES:

CLINICAL INSTRUCTION:

DIRECTOR OF THE MOVEMENT DISORDER/ NEURODEGENERATIVE DISORDERS CLINIC AT UTHMS 2001- Present Director of the Movement Disorders Fellowship Program for The University of Texas Medical School at Houston

Established UT MOVE 2001- this program is a unique and nationally recognized subdivision of clinical expertise at the University Of Texas Department Of Neurology. Currently the UT MOVE clinic sees the largest volume of patients in the UT Physicians Neurology Clinics.

July 2007- Texas Medical Board Health Education Commission- Accredited our Movement disorders fellowship for two years and endorsed training two postgraduates per year.

Purpose The UT MOVE clinic program offers focused attention on the neurological conditions of motor systems disruption, including the movement disorders, cerebral palsy, spasticity, the neurodegenerative diseases and dementias. It incorporates both an adult, geriatric and pediatric population, with expert faculty in each area. The faculty and participants in this program offer expertise in diagnosis, management, as well as medical and surgical therapeutic interventions for the specific disease states. Mya Caryn Schiess, M.D 10 Curriculum Vitae

Activities There are three major objectives for the UT MOVE Movement Disorders Program including 1) Clinical Care, 2) Education, and 3) Clinical and Basic Science Research. Wrote the UT Move Fellowship Training Handbook. Developed the only neurology directed Spasticity Management Clinic and currently have the largest Intrathecal Baclofen (ITB)pump population selected and managed by neurology in the USA. Developed an active surgical program for Deep Brain Stimulation for Parkinson’s disease, Dystonia, and Tremor.

SERVICES AVAILABLE TO THE COMMUNITY AND REGION AT UT MOVE CLINIC

. Diagnosis, pharmacological and surgical treatment and management for all the movement disorders (adult and pediatric populations) and the dementias. Largest populations include Parkinsonism, tremors, ataxias, dementias, focal and generalized dystonias, Alzheimer’s disease, normal pressure hydrocephalus, tics, fronto-temporal dementias, multisystem atrophy, and mild cognitive impairment. . Deep Brain Stimulation selection of candidates and programming- for appropriately selected Parkinson cases, essential and other tremor, dystonia, . Distinction- Designated Regional/National Training Site for DBS selection and programming. . Distinction- Invited and accepted into the Parkinson Study Group May 2005. The Parkinson Study Group is an international and nationally recognized body that governs the many clinical trials, coordinates multi-center research and has developed personal and professional standards for conducting clinical trials and research. . Spasticity Management regardless of etiology with Intrathecal Baclofen Pumps; including proper selection of appropriate candidates, performing intrathecal baclofen trials, pump refills and programming and all maintenance of ITB post implant. Spasticity population includes adults and pediatric ages with stroke, multiple sclerosis, spinal cord injury, traumatic brain injury, cerebral palsy. . Distinction- Designated Regional /National Training Site for ITB selection, trials, refills and programming.

I. Management of focal Spasticity and focal dystonia with Botulinum Toxin Injections. Population includes adults and pediatric ages with blepharospasm, cervical dystonia, focal limb dystonia, hemifacial spasm, writer’s cramp, refractory headache, spastic monoplegia, etc. II. Diagnosis and treatment of all sleep disorders associated with neurodegenerative diseases, including non-REM sleep behavior disorder, restless leg syndrome, apneas, sleep attacks etc. III. Weekly personal supervisory Responsibilities and Activities include:

. Five Half-day Ambulatory Clinics per week General Neurology Movement Disorders/Neurodegenerative Diseases. . Supervision and teaching of Resident rotating thru clinics . Supervision and teaching of Movement Disorder Fellow Mya Caryn Schiess, M.D 11 Curriculum Vitae

. Conducting and teaching with clinical trials on Rating Scales and Classification Schema; outcomes research in medical and surgical management for subtypes of Parkinson’s disease. . Half-day clinic per week for Movement Disorders- Video-taping/Rating Scales and pre-operative evaluation for Deep Brain Stimulation (DBS) or Pallidotomy procedures; DBS programming and post-operative follow up video and rating scales.

UT MOVE LECTURE SERIES FOR MOVEMENT DISORDERS AND NEURODEGENERATIVE DISEASES: ONE HOUR LECTURES AUDIENCE – RESIDENTS, FELLOWS, STUDENTS Idiopathic Parkinson’s Disease Part I Abnormal Tone-Spasticity And Rigidity Idiopathic Parkinson’s Disease Part II Spasticity Management – Botox Injections And Essential Tremor ITB Therapy Other Tremor Dementia – DAT And Cortical Dementias DBS Therapies For Parkinson’s Disease, Tremor Dementia – Fronto-Temporal, Lobar And And Dystonia Subcortical Dementias Generalized Dystonia/DYT1-13 Diffuse Lewy Body Disease Focal Dystonia Normal Pressure Hydrocephalus Botulinum Toxin-Basic Science And Mechanism Neuropsych Testing And The Treatment Of Of Action Dementias Botulinum Toxin Injection Therapy For Focal Ataxia – Spinocerebellar Diseases Dystonia; Cervical Dystonia Writers’ Cramp Dyskinesias - Drug And Paroxysmal Botulinum Injection Therapy For Hemifacial Restless Leg Syndrome Spasm Blepharospasm. Chorea/Huntington’s Disease/HDL 1 & 2 Botulinum Injections For Hyperhydrosis, Myoclonus/Focal/Segmental/Myoclonus – Sialorrhea, Headache Dystonia Syndrome Wilson’s Disease Copper Dysmetabolism

DIRECTOR OF THE MOVEMENT DISORDERS FELLOWSHIP PROGRAM

Texas State Board of Medical Examiners approved fellowship. Non-standard program funded by Hermann Memorial Hospital Foundation as a one to two year PGY 5 or PGY 6 fellowship. Requires one-on one supervision and training of fellow, established in 2001. UT MOVE specifically Dr. Mya Schiess- Principle Investigator for the Parkinson Study Group

DIRECTOR OF THE NEUROLOGY BOTOX INJECTION CLINIC FOR UTHMS

Supervision and teaching of residents/ fellow Botox Injection techniques, patient selection, indications, management and billing/coding. Average 30 patients a month treated with Botox injection therapy with disease profiles of cervical dystonias, focal dystonia, limb spasticity, hemifacial spasm, blepharospasm, muscle spasm, refractory headache, hyperhydrosis and hypersalivation.

DIRECTOR OF MOVEMENT DISORDER CLINIC FOR LBJ HOSPITAL Mya Caryn Schiess, M.D 12 Curriculum Vitae

Provide specialty neurological care to patients with Parkinsonism, spasticity, tremors, dystonia, and other movement disorders. Once a month clinic that provides subspecialty patient care; average 17-20 patients per clinic.

NEUROLOGY OUTPATIENT CLINIC

Provide specialty neurological care to patients diagnosed with Movement Disorders and Neurodegenerative Diseases as well as some General Neurological disorders.

NEUROLOGY CONSULTANT AT LBJ HOSPITAL

Provide Consultation to patients in the outpatient clinics

NEUROLOGY CONSULTANT AT RICHMOND STATE SCHOOL MHMR, RICHMOND TEXAS 1995- 2005

Two Neurology Clinics per month and On Call to RSS for consultation Admit to UT_HMS Hermann Hospital several cases per month for tertiary care Provides excellent teaching population for medical students and residents. Provide Vagal Nerve Stimulation placement in collaboration With neurosurgery for intractable epilepsy patients. Since 2003, UT MOVE clinic has provided consultation and specialty care for Richmond State School Clients.

NEUROLOGY WARD AND CONSULT ATTENDING

MEMORIAL HERMANN HOSPITAL

8- 12 weeks General Neurology Wards and Consults with 6 hours teaching and clinical care per day.

EDUCATIONAL PROGRAMS - ADMINISTRATIVE:

DIRECTOR OF NEUROLOGY RESIDENCY TRAINING - APPOINTED JULY 2002 Our training program currently has an A+ rating and 5 years accreditation since last site visit in April 2003. I was personally responsible for writing and editing the first version of our Program Information Form (PIF, 508 pages) to be submitted on-line in the history of the department to the RRC/ACGME. As program Director, I am driven by the principle that a successful training program has to have balance between clinical service/ experience and educational didactics. To that end and given the demand on our services by our four training institutions, I have petitioned and won approval from the RRC to increase our resident complement over these three years from 12 to a complement of 17. Since becoming program director, our program has had very successful match outcomes and we have been continuously at a full resident complement. Our Mya Caryn Schiess, M.D 13 Curriculum Vitae

ACGME accredited Residency Training Program residency slots are funded by Hermann Memorial Hospital, Methodist Hospital, M. D. Anderson Cancer Center, and LBJ Hospital Harris County District, and Methodist Neurological Institute.  Petitioned the RRC and obtained an approved increase in resident match to 5 per year in 2004  Petitioned the RRC in 2005 for an increase in complement to 17 and the addition of the Methodist Neurological Institute as a training institution. Director Duties and Responsibilities: Arrange the Rotation Schedules for the Residents in compliance with ACGME requirements for successful completion of all residency requirements for each resident. Established and created the Neurology Handbook 2001 Edit Neurology Handbook for the Residency Program every year Create every year the Neurology Rotation Schedule – Monthly Block Rotation Schedule Supervise/ evaluate and keep files on 15-19 Residents Created Core Competency Assessment Tools Created the Evaluation tools for Resident and Faculty including Monthly rotations, and the bi-annual Direct Faculty Evaluation in the Ambulatory Continuity Clinic Created Goals and Objectives for Residency Training Program and all Rotations Created and Formulated All Policies For UT Neurology Resident Training Program; including the Supervision Policy, Duty-Hours, Moonlighting, Discipline, Grievance and Complaints Process, Resident Selection and Eligibility, Promotion and Dismissal 2007-2009 Created a separate Neurology Residency Educational Syllabus and Handbook Created the internal structure for the five NEX Clinical Exams required for advancing to board eligibility and replacing the part II oral boards in Neurology.

Administrative and Certification Accomplishments as Residency Program Director: Addressed the 14 citations toward the program in April 2003 after becoming Program Director and completed the first on-line Program Information Form (PIF) for UTHMS-Neurology. The residency training program received full accreditation for 5 years with no citations from the ACGME/Neurology RRC. Underwent the second accreditation and site visit March 11, 2009 and received full accreditation for 3 years from the ACGME/Neurology RRC.

DIRECTOR OF EDUCATION FOR NEUROLOGY RESIDENTS TRAINING PROGRAM APPOINTED JULY 1999 Mya Caryn Schiess, M.D 14 Curriculum Vitae

Coordinated and scheduled the daily noon didactic lectures to Neurology Residents from 7/99 thru present; including comprehensive lecture series on neuroanatomy, neuro-opthamology, neuropharmacology, neurophysiology, psychiatry, and medical ethics. Education director for Neurology Grand Rounds, invited lecture series for every Friday of the month, which requires coordinating speakers and sponsorship. Established Core Curriculum on Movement Disorders with lectures that define the symptomatology by clinical exam, mechanism, and describe etiology and associated disease states and treatment.

INSTRUCTION AND TEACHING

Neurodegenerative Diseases - MSII class 2003, 2004, 2005

Clinical Correlates in Upper Motor neuron dysfunction - MSI class Clinical Correlates in Ataxia - MSI class

Core Lectures in Movement Disorders for Internal Medicine Residents – American Board Core lecture and MKSAP

UTSMH Master Teacher for 2002-2005 – Teaching Residents How to Teach – included 21 case based vignettes for Clinical Neurology Training

PBL Case Writer for Multiple Sclerosis Exam Case and Pernicious Anemia/Subacute Combined Degeneration of the Spinal Cord February/March 2001 PBL Case Rewrite for Clem Johnson – Parkinson disease, 2004-2005, November neuroscience section.

PBL Facilitator Period II Oct 15th through Dec 5th 2001

Clinical Practice Exam – exit examinations for the 4th year medical students- Exams involve half day of evaluations- 4 per year.

“Principals-Disorders of the Nervous System “ in Principles of Pathology 2005 Histopathological Basis for Disease. 90 minute lecture Pathology Dept. graduate students, October 31, 2005.

Coordinate and Staff (critic and review articles) for the monthly Neurology Journal Club

Coordinate and schedule the weekly CME accredited Neurology Grand Rounds from 7/99 thru present

Clinical Vignettes for neurology Board Review Bimonthly Jan- May 1999-yearly Mya Caryn Schiess, M.D 15 Curriculum Vitae

Neurobiology of Disease Course 9/99- 12/99 Description of Movement Disorders; Pathophysiology of Extrapyramidal Movement Disorders; Medical Treatment of PD and Related Disorders Neurobiology of Disease Course 9/2007- Non-Alzheimer’s Dementias

2008- present Created the MS4 One Month Elective Rotation in Movement Disorders- very successful rotation that has filled every month and exposes the MS4 to the outpatient specialist clinic and requires they learn the approach to tremor, dystonia, parkinsonism, all abnormal movements and cognitive impairment disorders; botox injection clinic, intrathecal baclofen spasticitiy clinic, DBS selection and programming, microelectrode intraoperative recording for DBS and clinical research protocols.

CURRENT RESEARCH /CLINICAL RESPONSIBILITIES

PAST LABORATORY RESEARCH:

The Analysis of Central Dopamine and Serotonin electrophysiology and pharmacology with electrophysiological and morphological typing of amygdala neurons.

The neurobiological substrate and pathophysiology underlying schizophrenia;

The mechanism of activity at the neuronal membrane level of the antipsychotic drugs;

The effects on signal transduction in animal models of psychiatric diseases and of the neuroleptics.

Investigation of the amygdala's functional interaction with the extrapyramidal system, motor cortex and brainstem as these relate to neurodegenerative diseases; such as Parkinson disease.

The role of serotonin at the level of the amygdala in influencing VTA and Substantia nigra dopamine transmission.

The role of serotonin in movement disorders.

The role of amino acids and specifically Glycine, Glutamate, and GABA in the pathophysiology of Parkinson’s disease.

The activity of glutamate and glycine at the NMDA receptor at the level of the subthalamic nucleus and globus pallidus internus.

LABORATORY METHODS:

 Electrophysiology Methods (includes): Mya Caryn Schiess, M.D 16 Curriculum Vitae

in vivo animal preparation current clamp and voltage clamp recording extracellular single unit recording synaptic stimulation and potential recording microiontophoresis in vitro slice preparation intracellular single unit recording

 Histology/Morphology/ Neuronal Cell Labeling and Staining  Chronic Drug Treatment Protocols  Treated Animal Behavioral Rating Protocols  High Pressure Liquid Chromatography of 5-HT, HVA, 5-HIAA, DA, DOPAC, 5- HTP, Tryptophan, NE, Amino Acids in ventricular CSF of Movement Disorder patients and Neurological controls.  Extracellular single unit and multi unit microelectrode recording of neuronal activity from striatal and pallidal neurons intraoperatively during posteroventral pallidotomy procedures.  Cell Cultures; CSF antibody, ELISA ; DNA gel laddering analysis

CLINICAL RESEARCH INTERESTS:

Creating classification criteria and validation of classification criteria for the tremor dominant, mixed and akinetic-rigid subtypes of Parkinson’s disease. Correlating the differences in transmitter profiles as determined by HPLC analysis of ventricular cerebrospinal fluid between the subtypes and the expression of specific disease symptomatology. Clinical trials in modifying the rate of progression within the akinetic-rigid versus tremor dominant subtypes of Parkinson’s disease by addressing the biochemical differences between the subtypes.

RATING SCALES:  Certified in UPDRS, Tremor, Dyskinesia and Dystonia Rating Scales  Certified in NIH Stroke Scale  Certified in Barthel Index  Classification of Parkinson’s Disease into Akinetic-Rigid,Tremor or Mixed Subtypes

PROPOSED PILOT STUDIES/ CLINICAL TRIALS:

Assess the role of the caudate nucleus in eye movements and orienting in Parkinson’s disease.

Intra-operative electrophysiology analysis and signal pattern correlation with disease symptomatology during Deep brain Stimulation electrode placement for Mya Caryn Schiess, M.D 17 Curriculum Vitae

PD, ET and Dystonia.

Effects of anti-Parkinson’s Disease medicines on volitional and reflexive eye movements.

Effects of DBS on reflexive and volitional eye movements and orienting in PD.

The role of CGRP in the pathogenesis of heart failure and Sudden Infant Death Syndrome

The Role of Cytokines and Chronic Inflammation in the Pathogenesis of Parkinson Disease

The Effects of DBS on Motor Scores and Quality of Life in the Akinetic-Rigid versus Tremor Dominant Idiopathic Parkinson’s Disease

Neuroimaging and CSF/Serum analysis in REM Sleep Behavior Disorder to Identify Pre-Motor Biomarkers for the Initial Stages of Parkinson’s Disease

CURRENT GRANT SUPPORT:

MEDICAL RESEARCH GRANTS

Submitted R01- NINDS “Cognitive, Non-motor and Imaging Biomarkers for Diagnosis and Progression in Parkinson’s Disease” PI Mya Schiess, MD

Submitted R01- NINDS “ The Role of Inflammatory Mediators in Parkinson's Neurodegeneration “. coPI Mya Schiess, MD

SUBMITTED NIH-T32- Research Fellowship Grant for Movement Disorders 6/2008 Physician Scientist Training Movement Disorders, 2 year training proposal for 4 postgraduate neurology fellows

2/2008- 2009 123 I-ALTROPANE® Reference Image Acquisition in Subjects with Diagnostically Uncertain Tremor (AIM) AIM study; PI Mya Schiess

8/2008 Cross-Sectional Cohort Study of Laboratory and Clinical Patterns in Early PD; Early PD Biomarkers PI Mya Schiess; Co-PI Erin Furr Stimming

8/2008 A Natural History Analysis of Rapid Eye Movement Sleep Behavior Disorder as Prognostic for Parkinson’s Disease; RBD Longitudinal PI Erin Furr Stimming & Mya Schiess Mya Caryn Schiess, M.D 18 Curriculum Vitae

7/2008- An 8-week, prospective, randomized, double-blind, double-dummy, active- PRESENT controlled, multi-center comparison study of the effects of Stalevo® versus (10%) immediate release carbidopa/levodopa on non-motor symptoms in patients with idiopathic Parkinson’s disease and demonstrating non-motor symptoms of wearing off; PI Mya Schiess; NOVARTIS; Stalevo vs Carbidopa/Levodopa

2008-PRESENT Kanaly Fund for Parkinson Disease Research, PI Mya Schiess; Biomarkers (130,000) for PD: Early Detection and Neuroprotective Therapies.

2002-2007 National Institutes of Neurological Disease and Stroke “Attention and (10% Eye Movements in Parkinson’s Disease” PI: Anne B. Sereno, Ph.D. funding) Neurobiology and Anatomy Co-PI: Mya C. Schiess,

“Assessment of Quality of Life for Spastic Hemiplegic Stroke after 2003-2006 Intrathecal Baclofen Pump Placement “PI: Mya Schiess, MD 230,000.00 Medtronics Incorporated. (estimated over 2-1/2: years – direct and indirect costs)

“Evaluation of the Effectiveness of Subthalamic Deep Brain Stimulation 2002-2007 and Its Effect on Neuropsychological Function in the Treatment of 75,000.00 Medically Intractable Parkinson’s Disease “ PI Gage Van Horn, MD, Mya Schiess, MD Sponsored by Houston Area Parkinson’s Society

“Evaluation of the Efficacy and Safety of ALTROPANE for 2004-2005 Differentiating Parkinsonian Syndromes from Non-Parkinsonian 115,000.00 Syndromes in Patients with Tremors “PI: Mya Schiess, MD, Boston Life Sciences, Inc.

2005-2008 Teva Pharmaceutical Industries Ltd., Israel Adagio Clinical Study 185,000.00 Protocol. “A multicenter, Double-Blind, Randomized Start, Placebo- Controlled, Parallel-Group Study To Asses Rasagiline As A Disease Modifying Therapy In Early Parkinson’s Disease Subjects”. PI: Mya Schiess, M.D.

Kanaly Fund for Parkinson Disease Research 2005-2008 “The Role of Cytokines and Chronic Inflammation in the Pathogenesis of 75,000.00 Parkinson Disease” PI Mya Schiess, MD

PramiBID “ A randomized, double-blind, active( pramipexole 0.75 mg 2006-2008 TID) and placebo controlled efficacy study of pramipexole , given 0.5 mg 65,000 and 0.75 mg BID over a 12-week treatment phase in early Parkinson’s disease patients “. PI Mya C. Schiess , MD Co-PI Erin Furr , MD

ISPR Implantable System Performance Registry, Medtronic, Inc. PI Mya Mya Caryn Schiess, M.D 19 Curriculum Vitae

FEBRUARY Schiess, MD 2007 -PRESENT Alseres Sponsored; I123 Altropane study for undiagnosed tremor- AIM DEC 2008- PI Mya Schiess, MD 2009 Novartis Sponsored; 8 week blinded palcebo controlled study of effects 2009- of Stalevo on non-motor symptoms of PD PI Mya Schiess, MD

EDUCATIONAL GRANTS

2002-2005 Masters Teacher Award “Teaching Residents to Teach”, Mya 10,000.00 Schiess, M.D. UTHMS Sponsored Educational Award

2004-2005 Educational Grant to support Movement Disorder Research Fellow. 12,500.00 Awarded by Medtronic.

2005-2006 Educational Grant to support Movement Disorder Research Fellow 25,000.00 Training in Indication, Patient Selection, Programming for Deep Brain Stimulation. Awarded by Medtronic.

2005-2006 Teva sponsored Educational Support Grant for the Department of 10,000.00 Neurology Residents of 2005-2006

2005-2006 Educational Grant for the support of Department of Neurology Resident 20,000.00 Training: Allergan Botulinum Toxin Type A sponsored by the Neuroscience Division.

PAST GRANT SUPPORT:

2000-2001 Preliminary Data on MEG and Neuropathic Pain, Dementia and 15,000.00 Depression, PI Andrew Papanicolaou, Ph.D. Sponsor 4-D Imaging Clinical Co-investigator: Mya C. Schiess MD

1984-1990 National Institutes of Child Health and Human Development: Physician 1,200,000.00 Scientist Award, Principal Investigator, The Electrophysiology of the Sexually Dimorphic Nucleus of the Medial Pre-optic Area of the Rat.

1989-1991 Scottish Rite Schizophrenia Research Program, Intracellular 80,000.00 Electrophysiological Analysis of Chronic Neuroleptic Treatment at the Central Nucleus of the Amygdala, Principal Investigator: Mya Schiess, M.D.

1994-1995 Pearl and Aaron Forman Research Foundation, UTMB Small Grant Mya Caryn Schiess, M.D 20 Curriculum Vitae

12,500.00 Principal Investigator-Mya Schiess M.D., "Serotonergic Neuromodulation of Electrophysiologically and Morphologically Defined Cells in the Central Nucleus of the Amygdala".

1992-1994 Sponsored Research Project with the University of Texas Health Science 16,000.00 Center at Houston, Co-Principal Investigator- Mya Schiess, M.D., "The Effects of Agricultural Pesticides on the GABA/BZD Receptor of the Mammalian Central Nervous System".

1994-open Pfizer Inc., Research and Education Grant, PI-Mya Schiess, M.D. for 4,800.00 Analysis of Effects of Atypical Antipsychotics on Amygdala Membrane Physiology; $4,800; Funding Period September 1994-1999.

1996-1997 Soukup VM, Ingram F, Schiess, MC, Bonnen JC, Nauta HJW, Calverley 20,000.00 JR. Unilateral Posteroventral Pallidotomy: Prospective Analysis of the Cognitive Sequelae. Source: Houston Area Parkinson's Society (HAPS).

PUBLICATIONS AND PRESENTATIONS

ABSTRACTS

Schiess, M.C., Dudley, C.A., Moss, R.L.: Estrogen Priming Affects LHRH Sensitivity but No Beta Endorphin Sensitivity at the Midbrain Central Grey. Soc. Neuroscience Vol. 15; 285.5,1985.

Schiess, M.C., Jöels, M., and Shinnick-Gallagher, P.: Estrogen Priming Affected Medial Amygdala Neuron Excitability Recorded Intracellularly. Soc. Neuroscience,Vol. 13;306.5, 1987.

Schiess, M.C., Jöels, M. and Shinnick-Gallagher P.: The Effects of Dopamine on Central Amygdala Neurons, in vitro Intracellular Recording. Soc. Neuroscience, Vol. 18; 377.10, 1988.

Schiess, M.C. and Shinnick-Gallagher: P. D1 and D2 Dopamine Receptor Agonists decrease Inwardly Rectifying Currents in the Central Nucleus of the Rat Amygdala. Soc. Neuroscience, Vol. 19, Oct. 1989.

Schiess, M.C.: Chronic Haloperidol and Clozapine Treatment at the Central Nucleus of the Rat Amygdala. Soc. Neuroscience, 575.4, 1991.

Schiess, M.C.: Acute Clozapine Treatment Alters Active Membrane Properties at the Amygdala Central Nucleus. Soc. Neuroscience, Vol. 19, 158.5, 1993.

Zheng, H., Lakoski, J.M., and Schiess, M.C.: Serotonin Modulates Synaptic Transmission and Mya Caryn Schiess, M.D 21 Curriculum Vitae

Active Membrane Properties in the Amygdala Central Nucleus. Soc. Neuroscience, Vol. 19, 305.6, 1993.

Zheng, H., and Schiess, M.C.: Correlation of Electrophysiology and Morphology of Central Amygdala Neurons, Using Neurobiotin Intracellular Recordings. 7th Annual Sigma Chi Research Forum, February 9,1995, UTMB, Galveston, Tx.

James-Hewitt, E. and Schiess, M.C.: Frequent Intermittent Boluses of IV Lidocaine Cause CNS Toxicity. American Academy of Neurology Annual Meeting, #P0756, May 1995, Seattle, WA.

Schiess, M.C.: Atypical Neuroleptics, CLozapine and Olanzapine, have different effects on Central Amygdala Membrane Properties and Synaptic Potentials, presented as Abstract and Poster in IBC Conference, Schizophrenia, May 8-9, 1995, Philadelphia, PA.

Zheng, H. and Schiess, M.C.: Serotonin Modulates Synaptic Transmission at the Central Amygdala Nucleus, accepted # 05420, 1995 Society for Neuroscience.

Schiess, M.C. and Zheng, H: Intracellular Recordings from Neurobiotin Stained Neurons of the Central Amygdala Nucleus. #11240, 1995 Society for Neuroscience.

Zheng H., Schiess M.C., Nauta, H.J., Bonnen, J.G.: Concentrations of Free Dopamine, Serotonin, Norepinephrine and their Metabolites in Ventricular CSF of Parkinson's Disease Patients, Society for Neuroscience, 1996.

Soukup, V., Ingram, F., Schiess, M.C., Bonnen, G., Calverley, J., Nauta, H.: Cognitive Sequelae of Posteroventral Pallidotomy, National Academy of Neuropsychology, 1996.

Soukup VM, Ingram F, Schiess M.C., Bonnen JG, Nauta HJW, and Calverley JR. Cognitive Sequelae of Posteroventral Pallidotomy. Archives of Clinical Neuropsychology. (1997)

Schiess, M.C., Zheng, H., J.G. Bonnen, Soukup, V.M., Calverley, J.R., Nauta, H. J.: Concentrations of Amino Acids in Ventricular CSF of Parkinson's Disease Patients, Society for Neuroscience, 1997.

Bonnen, J.G., Schiess, M.C., H.Zheng, Soukup, V.M, Calverley, J.R., Nauta, H.J: Imaging- Intensive Posteroventral Pallidotomy: Technique and Results, Congress of Neurosurgery, 1997. J.G. Bonnen, Schiess, M.C., H. Zheng, V.M.Soukup, J.R. Calverley, H.J. Nauta, Amino Acids in Ventricular CSF of Parkinson’s Disease Patients, Congress of Neurosurgery, 1997.

Hollingsworth, C.L., Chaljub,G, Schiess, M.C., Bonnen, G, Nauta,H.J. Mandava, P: MR Imaging Guided Microelectrode Ablation of Posteroventral Pallidotomy for refractor Parkinson’s Disease, 83rd Annual Meeting of the Radiological Society of North America, 1997.

Schiess, M.C., Zheng, H., Bonnen, J.G., Nauta H.J, Soukup, V.M.: Correlation of Ventricular concentration of 5-hydroxy indole acetic acid (5-HIAA) and glycine to dominant Mya Caryn Schiess, M.D 22 Curriculum Vitae symptomatology in Parkinson’s disease. October 12, 1998; 5th International Congress of Parkinson’s disease and Movement Disorders, New York, NY.

Edwards, K., Schiess, M.C., Vickery, B., Dollar, L., McKenzie, D.: VigabatrinVGPRO101 Study Group Rational Polytherapy with Sabril (Vigabatrin) versus Carbamazepine or Phenytoin Monotherapy in the Management of Patients with Complex Partial seizures American Epilepsy Society, 1998.

Cain, A.E.,Amador, S.C., Alrefai, A., Schiess, M.C., and Sereno, A.B.: Medications Increase Reflexive Saccade Latencies in Parkinson’s Disease Patients, Society for Neuroscience, 2002.

Cain, A, Amador, S., Briand, K.,Alrefai, A. Schiess, M.C., Sereno, A.: Medications Reduce Errors in Antisaccade Tasks in Parkinson's Disease Patients, Movement Disorder’s International Symposium, Florida,USA, November 2002.

Izor, R, Fisher, S., Simpson, R., Johnson, K., Tran, T., and Schiess, M.C.: Intrathecal Baclofen Pump Therapy Improves Functional Motor Control and Quality of Life in Spastic Hemiplegia After Stroke, International Movement Disorders Society, Rome, Italy, June 2004.

Jagar AA, Amador SC, Schiess MC, Sereno AB. Dopaminergic Medication and Cognition in Parkinson's disease. Presented at the Society for Neuroscience 35th Annual Meeting, Washington, DC. , November, 2005.

Schiess, MC, Fisher, S, Izor, R, Furr, E, Simpson, R, Van Horn, G. Significant Tremor Control after STN-DBS in Tremor –Dominant Idiopathic Parkinson Disease, # 950274. 58th Annual Meeting of the American Academy of Neurology, San Diego, CA, April 2006.

Schiess, MC, Acosta, F, Izor, R, Fisher, S, Furr, E, Simpson, R “Functional Motor Improvement in Stroke Related Spastic Hemiparesis after Intrathecal Baclofen Therapy” AAN , Neural Repair, San Diego, CA., April 2006.

Schiess, MC, Furr, E, Kaur, B, Oh, I,Poindexter, B, Kott, M-L, Bick, D, Doursout, M-F, Bick, R, Cytokine Effects on Parkinson Associated Proteins, α-synuclein, Tau and Ubiquitin in Cultured Glial Cells: Localization and Densities by Deconvolution Fluorescence Microscopy, AAN, Boston ,MA, April 2007 .

Michelle Mann, Brian Poindexter, Mya Schiess,Roger Bick Calcium Movements in CGRP- treated, cultured skeletal muscles, examined by real- time and deconvolution flrorescence microscopy : a role for the peptide in tension headaches. 2007 Summer Research Program for Medical Students; UTHMS Research Forum, October 2007.

Hood AJ, Schiess MC, Sereno, AB Exogenous and endogenous covert orienting of attention in Parkisnon’s disease. 37th Annual Society for Neuroscience, San Diego, CA; Poster 634.1; November 2007 Mya Caryn Schiess, M.D 23 Curriculum Vitae

Schiess MC, Poindexter B, Hook D, Doursout M-F, Bick R Localization and density of PD associated proteins and cytokines after lipopolysaccharide treatments. #12; Movement Disorders Society 12th International Congress of Parkinson’s Disease and Movement Disorders, Chicago, Illinois, June 2008

Furr Stimming E, Oh IJ, Van Horn G, Simpson R, Schiess, MC, Sensitivity and Specificity of Levodopa Response in Predicting Deep Brain Stimulation Outcomes in Parkinson’s Disease. # 396; Movement Disorders Society 12th International Congress of Parkinson’s Disease and Movement Disorders, Chicago, Illinois, June 2008

Hood AJ, Amador SC, Schiess MC, Sereno AB Medication Improves Executive Function in Tremor- Dominant Subtype of Idiopathic parkinson’s disease. # 273; Movement Disorders Society 12th International Congress of Parkinson’s Disease and Movement Disorders, Chicago, Illinois, June 2008

MC Schiess, J Barnes, B Poindexter, I Oh, R Bick, CSF from Parkinson’s Disease Patients Differentially Affects α-Synuclein Density and Cell growth in Microglia compared to Astrocytes. Neurology, (Suppl 3), March 17, 2009.

M Schiess, M Schurdell, M Gordon, G, Kidder, B Poindexter, R Bick . Animal Model of Endotoxin Induced Neurodegeneration in Parkinson’s disease. Movement Disorder Society’s 13th International Congress, June , 2009.

M Schiess, J Barnes, M Gordon, B Poindexter, R Bick. CSF from Parkinson’s disease patients affects alpha-synuclein density and cell growth in microglia and astrocytes. Movement Disorder Society’s 13th International Congress, June , 2009.

I Oh, MC Schiess, G Van Horn, E Furr Stimming, The impact of Subtype and Disease Duration on Quality of Life in Parkinson’s Disease, Movement Disorder Society’s 13th International Congress, June , 2009.

Madan A , Schiess MC Intrathecal Baclofen Therapy Slows Progression in Multiple System Atrophy, Movement Disorder Society’s 13th International Congress, June , 2009.

Schiess MC, Ellmore T, Castriotta r, Bick d, Doursout M-f, Stimming E-F, Bick R, Volumetric MRI as an Image Biomarker for the Early Diagnosis of Parkinson’s Diseases. AAN Abstract for 2010.

Hood AJ, Schiess MC, Sereno AB, Adjuvant Medication Can Decrease Deep Brain Stimulation –Induced Impulsivity: A saccade study in Parkinson disease. AAN abstract for 2010.

Ellmore T, Hendley K, Aalbers B, Furr-Stimming E, Hood A, Castriotta R, Schiess M . Substantia nigra rest state fMRI correlation differences between REM sleep behavior and early PD patients. MDS 15th International Congress, June 2011. Mya Caryn Schiess, M.D 24 Curriculum Vitae

Hendley K,

ARTICLES:

Schiess, M.C., Dudley, C.A., Moss, R.L. Estrogen priming affects the sensitivity of midbrain central grey neurons to microiontophoretically applied LHRH but not Beta-endorphin. Neuroendocrinology, 46; 24-31, 1987.

Schiess, M.C., Jöels. M., Shinnick-Gallagher, P. Estrogen Priming Affects Excitability of Medial Amygdala Neurons in an in vitro Preparation. Brain Research, 440-2; 380-385, 1988.

Schiess, M.C., Asprodini, E., Rainnie D. and Shinnick-Gallagher, P. The Central Nucleus of the Rat Amygdala: in vitro Intracellular Recording, Brain Research, 604:283-297, 1993.

Soukup V. M, Ingram F, Schiess M.C., Bonnen J.G, Nauta H.J.W, and Calverley J.R. Cognitive Sequelae of Unilateral Posteroventral Pallidotomy, Archives of Neurology, 54:947-050, 1997.

Nauta H.J.W., Bonnen, Soukup,V.M.Gonzales, A, and Schiess, M.C. Imaging-Intensive Guidance with Confirmatory Physiological Mapping for Neurosurgery of Movement Disorders, Society of Photo-Optical Instrumentation Engineers, Reprinted from Proceedings of Surgical Assist Systems, Vol. 3262, 253-258, 1998.

Soukup, V.M., Ingram, F, Grady, J.J, Schiess, M.C.: Trail-Making Test: Issues in Normative Data Selection, Applied Neuropsychology, 5:2, 65-73, 1998.

Schiess, M.C., Callahan, P.M. and Zheng, H. Characterization of the Electrophysiological and Morphological Properties of Rat Central Amygdala Neurons in vitro. Wiley-Liss, Inc. J Neuroscience Research, 58:663-673, 1999.

Soukup, V.M., Bimbela, A, and Schiess, M.C.: Recognition Memory Faces; Reliability and Validity of the Warrington Recognition Memory Test (RMT) in a Neurological Sample, J Clinical Psych in Medical Settings, Vol 6, No.3, 287-293,1999.

Schiess, M.C.,Zheng, H, Soukup, V.M., Bonnen, J.G., Nauta J.H.: Parkinson’s Disease Subtypes: Clinical Classification and Ventricular Cerebrospinal Fluid (V-CSF) Analysis, Parkinsonism and Related Disorders, Elsevier, 6:69-76 , 2000.

Van Horn, G., Schiess, M.C.: Pallidotomy: Refining the Technique, Lancet Neurology Network www.lancetneuronet.com ,4 (1), pp1-3, 2000.

Van Horn, G., Soukup, V.M, Schiess, M.C., Subthalamic DBS: Neurobehavioral Concerns; editorial in Archives of Neurology, 58:8, 1205-1206, August 2001. Mya Caryn Schiess, M.D 25 Curriculum Vitae

Schiess, M.C., Nonsteroidal Anti-inflammatory Drugs ( NSAIDs) Protect Against Parkinson’s Neurodegeneration: Can an NSAID a day keep Parkinson Disease Away ? Archives of Neurology, vol 60,1043-44, August 2003.

Bick, R., Poindexter, B. and Schiess, M.S.,: Localization of Calcitonin Gene-Related Peptide in Cardiomyocytes; Comparison of Neonatal and Dedifferentiating Cells to Adult Myocytes, Peptides, Volume 26, Issue 2, pp 331-3-, February 2005.

Schiess, M.C., Poindexter, B. and Bick, R.: The effects of CGRP on calcium transients of dedifferentiating cultured adult rat cardiomyocytes compared to non-cultured adult cardiomyocytes: possible protective and deleterious results in cardiac function. Peptides, Volume 26, Issue 3, pp 525-530, March 2005.

Bick, R., Poindexter, B., Davis, R. and Schiess, M.C.: Determination of the site of action of calcitonin gene-related peptide in the alteration of intracellular calcium levels in adult and neonatal rodent myocytes. Peptides, Volume 26, Issue 11, pp2231-2238, November 2005.

Amador, SC, Hood AJ, Schiess, MC, Izor, R, Sereno, A: Dissociating Cognitive Deficits involved in voluntary eye movement dysfunctions in Parkinson’s disease patients. Neruopsychologia, 44, 1475-1482, 2006.

Francisco, GE, Yablon, SA, Schiess, MC, Wiggs, L, Cavalier, S, Grissom, S Consensus Panel Recomendations for the Use of Intrathecal Baclofen Therapy in Post-Stroke Spastic Hypertonia, Topics in Stroke Rehabilitation, 2006;13(4):74-85.

Ashley Hood, Silvia Amodort, Ashley Cain, Kevin Briand, Ali Alrefai, Mya Schiess, Anne Sereno, Levodopa slows prosaccades and improves antisaccades : An eye movement study in Parkinson’s Disease, Journal of Neurology, Neurosurgery and Psychiatry, 2007;78:565-570.

Schiess, Mya and Oh, Irene, Serum Uric Acid and Clinical Progression in Parkinson Disease: Potential Biomarker for Nigrostriatal Failure. Archives of Neurology,2008,vol.65 (No.6); 698- 699.

Bick RJ, Poindexter B, Kott MM, an Liang Y, Dinh K, Kaur B, Bick D, Doursout M-F, Schiess MC, Cytokines disrupt intracellular patterns of Parkinson’s disease associated proteins alpha- synuclein, tau and ubiquitin in cultured gilal cells, Brain Research, 2008, 1217;203-212.

Roger Bick, Michelle Mann, Brian Poindexter and Mya Schiess, Calcium movements in CGRP- treated, cultured skeletal muscle cells: Is there a role for CGRP in Tension Headaches? International J Peptide Research and Therapeutics , 2008,14:193-199.

Hallevi H, Oh I, Valdez S, Kidder B, Schiess M. Postencephalitic Hemiparkinsonism: Clinical Imaging Correlation. Archives of Neurology 2008,vol.65( No.6); 837. Mya Caryn Schiess, M.D 26 Curriculum Vitae

Dinh K, Poindexter BJ, Barnes JL, Schiess MC, Bick R. Fluorescence Microscopy and 3D image reconstruction of cytokine initiated disruption of the Parkinson disease associated proteins alpha-synuclein,tau and ubiquitin in cultured glial cells. Cytokine, 45,2009,179-183.

Yaltho T, Schiess MC, Furr Stimming E, Acute bilateral basal ganglia lesions and chorea in a diabetic-uremic patient: Clinical Imaging Correlation. Archives of Neurology,Vol 67(2), 2010, 246-247.

Schiess M, Oh I, Stimming E, Lucke J, Acosta F, Fisher S, Simpson R. Prospective 12 Month Study of Intrathecal Baclofen Therapy for Post Stroke Spastic Upper and Lower Extremity Motor Control and Functional Improvement . Neuromodulation, January, 2011, DOI:10.1111/j.1525-1403.2010.00308.x

Ellmore T, Hood AJ, Castriotta R, Stimming EF, Bick R, Schiess MC. Reduced Volume of the Putamen in REM Sleep Behavior Disorder Patients. Parkinsonism and Related Disorders, 2010,16: 645-649.

Mya C. Schiess, Jennifer L. Barnes, Timothy M. Ellmore, Brian J Poindexter, Kha Dinh, Roger J Bick. CSF from Parkinson disease Patients Differentially affects cultured Microglia and Astrocytes. BMC Neuroscience 2010, 11:151 doi:10.1186/1471-2202-11-151

Anita Madan and Mya Schiess, Intrathecal Baclofen Therapy Slows Progressive Disability in Multiple System Atrophy , Neuromodulation (17) 21:06 2011. DOI:10.1111/j.1525-1403.2011.00336.x

Ashley Hood, Mya Schiess, Anne Sereno Impulsivity after Deep Brain Stimulation of the Subthalamic Nucleus: A Saccade study in Parkinson disease. In review

CHAPTERS/PERIODICALS:

Molony, D.A., Evanoff, G. and Schiess, M.C.: Respiratory Disorders; Alkalosis and Acidosis. In Fluid and Electrolyte Disorders, edited by R.L. Tannen and J.P. Kokko, W.B. Saunders, 2nd edition, Philadelphia, pp. 391-449, 1990.

Molony, D.A., Schiess, M.C. and Dosekun, A.: Respiratory Disorders; Alkalosis and Acidosis. In Fluid and Electrolyte Disorders, Eds. Kokko and Tannen, W.B. Saunders, 3rd edition, Philadelphia, pp. 267-342, 1995.

Francisco, G., Kothari,S., Schiess, M.C., and Kaldis, T.: Rehabilitation of Persons with Parkinson’s Disease and Other Movement Disorders in Rehabilitation Medicine: Principles and Practice.4th ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2005. pg 809-828.

LETTERS/COMMUNICATION:

Van Horn, G. and Schiess, M.C.: Letter to the Editor re Immediate release and controlled release carbidopa/levodopa in PD: A 5 year randomized multicenter study, Neurology,55, July Mya Caryn Schiess, M.D 27 Curriculum Vitae

(1 of 2), p 156, 2000.

Soukup V.M, Ingram F, Schiess, M.C., Bonnen, JG, Nauta, HJW, Calverley, J.R. Reply to the Trepanier, Saint-Cyr, Lang and Lazano Letter, in Letters to the Editor, Archives of Neurology, 55, 883, 1998.

PRESENTATIONS/INVITED LECTURES:

REGIONAL/LOCAL:

05/1996 " Emergency Management of Adult Seizures" " Strokes"- What to do in the Pre-hospital Setting" Rural Emergency Education Network Telecommunications (REENT), Houston, Texas 04/1996 "Stroke- what it can mean to you and your family "MPS Media Production- Lecture to Community in Levine Hall, Galveston, Texas 04/1996 "Update on Research, Therapy and Legislation" "Functional Outcome of Image Intensive Pallidotomy Surgery" Seminar Houston Area Parkinson Society- Sixth Annual Symposium Instructors: Drs. Soukup, Bonnen, and Schiess for the City of Houston Multi-Service Center, Houston, Texas 03/2000 “Parkinson’s disease: Update on Medical Interventions”, Neurology Update , March 10, 2000, Houston, Texas. 06/2000 “COMT Strategies for the Parkinson’s patient- Case Studies” Houston Clinical Forum- sponsored by Novartis, June 13, 2000, Houston, Texas 03/2001 “Postural Instability”, Parkinson Foundation of Harris County invited lecture, March 16th, 2001, Houston, Texas 9/2002 “New Therapies for Movement Diisorders; DBS, ITB and BOTOX”. Houston, Texas, September 2002. 10/2002 “Introduction to Movement Disorders” TIRR and Combined UT/Baylor PM&R Residents: Houston, Texas, October 1, 2002. 01/2003 “Brain/Mind Function; What goes wrong in PSP”, Progressive Supranuclear Palsy Houston Society Lecture, Houston, Texas 06/2003 “Parkinson Disease- Definition, Diagnosis, New Treatment Options”. CME Seminar for TIRR Nurse Case Mangers and Social Workers Marriott Medical Center, Houston, Texas 02/2004 Willowbrook Methodist Hospital “Deep Brain Stimulation in the Treatment of Parkinson’s Disease: Young Onset Parkinson’s Disease.HAPS” Houston Area Parkinson’s Society, Houston, Texas Mya Caryn Schiess, M.D 28 Curriculum Vitae

09/2004 “Parkinsonism and Manganese Exposure” Welders at Risk: Channel 11 / CBS affiliate, Houston, Texas 11/2004 “Managing Your Parkinson’s Disease: Surgical Interventions: Deep Brain Stimulation Therapy for the Parkinson Patient”. HAPS 2004 Annual Symposium , Houston, Texas 9/2005 “Parkinson’s disease treatment has changed: Medication options, surgical options, and future options.” PR Community Education Campaign sponsored by Medtronic Inc., Houston, Texas. September 15, 2005. 6/2005 “Applications of Botulinum Toxin in contemporary Neurologic and Physiatric Practice”. Instructional Workshop arranged in cooperation with Physical Medicine and Rehabilitation alliance of the Baylor College of Medicine and The University of Texas Houston Health Science Center, Houston, Texas June 18, 2005. 9/2005 Houston Press Overstimulated How taking a Parkinson's disease wonder drug apparently makes some people want to gamble and have sex all the time By Todd Spivak Published: Thursday, September 15, 2005, Houston Press 9/2005 Pasadena Citizen “ Procedure helps man combat Parkinson's By:Jennifer Branch , Citizen reporter, Sept 16, 2005 Pasadena Citizen (circ: 17,175). 9/2005 “An update in treating Parkinson’s disease essential tremor, spasticity and dystonia”. Medtronic, Inc., San Antonio, Texas. September 8, 2005. 4/2006 Houston Area Parkinsons’s Society “Early Parkinson’s Disease – an Overview of Disease and Management’. 9/2006 HAPS Early Parkinson’s Disease – an Overview of Disease and Management 2/2007 HAPS Early Parkinson’s Disease – an Overview of Disease and Management 2/2008 HAPS Non-motor Symptoms of Parkinson Disease 4/2008 HAPS Update on Parkinson’s Research 6/2008 Gulf Coast PA Society- Dopamine Management Theory: How Azilect can be used as Monotherapy or Adjunct Therapy in Parkinson disease. 1/09 Overview of Essential Tremor: Medical and Surgical treatment Options Katy, TX ET Support Group

3/31/09 Movement Disorders: PD Diagnosis and Treatment Psychiatry Residency Training Program, HCPC

4/4/2009 Community Information Sharing, Seminar on Parkinson’s Science: Innovations and New Perspectives, sponsored by HAPS and NPF; Houston, Texas

6/27/2009 Overview on Parkinson’s disease; Diagnosis ; Non-Motor Symptoms; Treatment and Management, Houston Area Parkinson’s Society community lecture Mya Caryn Schiess, M.D 29 Curriculum Vitae

7/17/2009 “Non-motor symptoms in PD- recognition and management” Houston Area Chapter for National Parkinson’s Foundation, community lecture

Oct 24, 2009 Overview on Parkinson’s disease; Diagnosis ; Non-Motor Symptoms; Treatment and Management, Houston Area Parkinson’s Society community lecture No. 13 2009 Neurology Grand Rounds “ Parkinson Disease: a neuroinflammatory process”

NATIONAL:

11/1996 “Parkinson ’s Disease” Medstar Channel 11 Television Series, Houston, Texas 2/2002 “Management and Control over Refractory Seizures in MR/DD Population”. 31st Annual APDDA conference. New Orleans, LA., February 19, 2002. 4/2003 “Case Studies of Keppra (leviteracetam) use in the Developmentally Disabled Population” Annual MHMR/APDDA conference, Austin, Texas, April 1, 2003. 11/2003 “Patient Selection Process for Deep Brain Stimulation” Medtronics Incorporated Symposium: Lecturers: Dr. Schiess, Dr. Tintner, and Dr. Simpson, Marriott Medical Center Hotel, Houston, Texas 02/2004 “Intrathecal Baclofen for the treatment of Spastic Hemiplegia Due to Stroke”, Channel 11 News, Houston, Texas 03/2004 “Intrathecal Baclofen Pumps in the Treatment of Spastcity” Nationally Televised Lecture Series to over 90 affiliated TV stations Medstar- Healthcare Network., February thru March. 09/2004 “Parkinsonism and Manganese Exposure” Welders at Risk: Channel 11 / CBS affiliate, Houston, Texas 10/2004 “ITB Therapy for the Adult Neurologist” Faculty Presenter at Cleveland Clinic, Cleveland, Ohio 11/2004 “Managing Your Parkinson’s Disease: Surgical Interventions: Deep Brain Stimulation Therapy for the Parkinson Patient”. HAPS 2004 Annual Symposium Houston, Texas 6/2005 “Spasticity Management” Medtronics sponsored workshop, Cleveland, Ohio, June 2005. 9/2005 “Parkinson’s disease treatment has changed: Medication options, surgical options, and future options.” PR Community Education Campaign sponsored by Medtronic Inc., Houston, Texas. September 15, 2005. 1/ 2006 “Spasticity Management in the Patient with Stroke or MS; the role of ITB therapy.” National Audience : 1. Spasticity: Pathophysiology and Diagnosis in the Context of Other Movement Disorders Mya Caryn Schiess, M.D 30 Curriculum Vitae

2. Intrathecal Baclofen Screening Trial in the Stroke Patient 3. DBS Therapy in Movement Disorders 4. Patient Selection for ITB Therapy I the Stroke Population January 13-15 2006 San Francisco , CA

2/13/2006 ITB Therapy in the Stroke Population, Dallas Community Dinner Seminar , Dallas, Texas 2/14/2006 ITB Therapy for Spasticity Management in the Stroke Population, Baylor PM& R Grand Rounds , Dallas, Texas 4/2006 Platform presentation “Functional Motor Improvement in Stroke Related Spastic Hemiparesis after Intrathecal Baclofen Therapy” American Academy of Neurology , Neural Repair, San Diego, CA. 2/ 9-11, 2007 Texas Neurological Society meeting Invited Speaker for “ Clinical Update in Parkinson’s Disease” Austin, Texas 10/2007 Spasticity Management- ITB therapy in Post Stroke Hemiplegia ITB Therapy in Adult Spasticity; Dosing Guidelines for ITB therapy Functional Improvement in Upper Extremity with ITB Therapy Denver, Colorado, Oct 4-6 2007

11/2008 Neurology Grand Rounds CME approved; “Adult Spasticity Management: Case Presentation and Review of Intrathecal Baclofen Therapy” UTHMS, Houston, Tx

11-19 2008 Invited Speaker New York Medical College at Westchester, NY Neurology & Neurosurgery Grand Rounds CME approved;“ “Intrathecal Baclofen Therapy for Post Stoke Spastic Hemiparesis”, Nov 19th, 2008, Westchester, NY

Oct , 2009 National neurology Residency Teaching Conference- Common Movement Disorders, Chicago, Il. Oct 16-18, 2009 Parkinson’s disease, tremor, dystonia; Spasticity; Therapies – DBS, ITB, Botulinum toxin.

Oct, 2009 National Spasticity Management- Adult and Pediatric, Neurology and PM&R Washington, DC, Oct 30/31, 2009. Advanced ITB therapy and Rehab.

August 28th , 2010 National Ataxia Foundation Seminar on Ataxias, Update on diagnosis, therapies and research Speaker: Mya SChiess, MD, Brian Aalbers, DO

Feb. 2011 Deep Brain Stimulation- Fellows Seminar- Practices and Practice San Francisco, CA Advanced DBS therapy and Practice Quidelines

Feb.19th 2011 Houston Area Parkinson’s Disease Society Newly Diagnosed Saturday Conference; Part I PD Diagnosis Part II Therapies and Management of PD, Part III Non-motor Symptoms in PD Speakers Drs Mya Schiess & Katie Hendley

April 30, 2011 Houston Area Parkinson’s Disease Society Annual Symposium Mya Caryn Schiess, M.D 31 Curriculum Vitae

“Update on DBS Therapy in PD”, Mya Schiess MD and Richard Simpson MD, PhD “Sleep well, Live well; understanding the connection between sleep and Parkinson’s disease” Mya Schiess, MD United Way , Houston , Texas